Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
extension tags : Cancer save search
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
BYSI | $2.44 6.55% 66K
|
Health Technology
|
| O: 0.0%
H: 12.18%
C: 11.22%
first lung cancer study
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.57 0.12% 34K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.23 -1.12% 300K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.83 -2.82% 60K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.55 -4.57% 140K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $66.55 -0.72% 1.6M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.525 1.01% 310K
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Published: 2023-10-27 (Crawled : 11:00) - globenewswire.com
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: 2.07%
H: 6.76%
C: 2.7%
lung trilaciclib indicate world cancer cell
OncoHost's PROphet® Platform to Support Henlius US-Based Phase III Trial for Patients with Extensive-Stage Small Cell Lung Cancer
Published: 2023-10-03 (Crawled : 19:00) - biospace.com/
SLGC | $2.1 -4.76% 34M
|
|
| O: -0.64%
H: 0.0%
C: 0.0%
prophet lung cancer cell trial platform
New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Published: 2023-07-31 (Crawled : 12:00) - globenewswire.com
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: 1.28%
H: 2.94%
C: 0.84%
lung trilaciclib world cancer publication cell impact
LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 15:00) - biospace.com/
NVCR | $12.175 1.0% 210K
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Published: 2023-06-06 (Crawled : 12:00) - globenewswire.com
ZLAB | $15.92 5.29% 130K
|
Health Technology
|
| O: -2.43%
H: 0.67%
C: -2.98%
NVCR | $12.175 1.0% 210K
|
Health Technology
|
| O: -9.53%
H: 0.68%
C: -37.04%
lung cancer cell extension trial
CEL-SCI’s Multikine Phase 3 Cancer Study Shows 43% Survival Extension
Published: 2023-03-08 (Crawled : 18:00) - biospace.com/
CVM | $1.462 -0.54% 11K
|
Health Technology
|
| O: 0.69%
H: 3.78%
C: -5.84%
extension multikine cancer study
Propulsion of Pancreatic Cancer Pipeline as Novel and Extensive 170+ Therapies Likely to Enter in the Treatment Domain | DelveInsight
Published: 2023-01-02 (Crawled : 16:00) - prnewswire.com
SNY | News | $46.82 -1.82% 510K
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.27 -0.74% 170K
|
Health Technology
| Email alert
Add to watchlist
RCUS 4 | $14.98 -3.36% 43K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.25 480
|
Health Technology
| Email alert
Add to watchlist
QLGN | $0.296 -6.03% 21K
|
Health Technology
| Email alert
Add to watchlist
BNTX | News | $88.55 0.07% 62K
|
Health Technology
| Email alert
Add to watchlist
AGEN A | $7.14 10.53% 520K
|
Health Technology
| Email alert
Add to watchlist
MRUS | $41.25 1.05% 240K
|
Health Technology
| Email alert
Add to watchlist
GRTX | $0.194 500K
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $731.46 -1.91% 700K
|
Health Technology
| Email alert
Add to watchlist
treatment cancer pancreatic
Extensive Stage Small Cell Lung Cancer Global Market Report 2022: Need of Potential Treatments to Improve Quality of Life Drives Sector
Published: 2022-12-22 (Crawled : 17:00) - prnewswire.com
AZNCF | News | $140.3 1.5K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
JAZZ | $108.03 -1.5% 89K
|
Health Technology
|
| O: -0.06%
H: 1.27%
C: 0.93%
AZN | News | $70.93 0.11% 2.3M
|
Health Technology
|
| O: -0.04%
H: 0.32%
C: 0.31%
lung global report life potential cancer market
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
Published: 2022-11-21 (Crawled : 14:00) - biospace.com/
LEGN | News | $46.705 -1.57% 220K
|
Health Technology
|
| O: 0.0%
H: 0.44%
C: -2.11%
lb2102 fda clearance lung biotech application cancer
G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer
Published: 2022-10-26 (Crawled : 14:00) - globenewswire.com
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: -0.62%
H: 5.64%
C: -0.81%
lung trilaciclib therapeutics cancer study initiated
COSELA® (Trilaciclib Hydrochloride for Injection) Now Approved in China to Decrease the Incidence of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Published: 2022-07-13 (Crawled : 14:20) - globenewswire.com
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: -2.25%
H: 15.98%
C: 9.06%
cosela approved china cancer
Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy
Published: 2022-06-02 (Crawled : 15:20) - globenewswire.com
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: -0.89%
H: 4.28%
C: 2.03%
trilaciclib asco cancer
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published: 2022-05-17 (Crawled : 15:20) - globenewswire.com
SRNE | $0.015 56K
|
Health Technology
|
| O: 4.17%
H: 6.0%
C: 4.67%
treatment license trial cancer enroll antibody
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
CANF | $1.93 -2.03% 600
|
Health Technology
|
| O: 88.98%
H: 8.33%
C: -10.42%
liver cancer namodenoson
Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Published: 2021-07-23 (Crawled : 16:00) - globenewswire.com
SRNE | $0.015 56K
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -5.13%
treatment lung cancer cancer antibody license
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer
Published: 2021-07-09 (Crawled : 12:15) - globenewswire.com
GALT | $3.435 1.63% 18K
|
Health Technology
|
| O: 43.48%
H: 11.11%
C: -12.88%
phase 1 positive results cancer trial topline galectin-3 phase 1b keytruda phase 2b
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: 0.47%
H: 0.42%
C: -1.04%
lung cancer potential cancer trilaciclib
G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer
Published: 2021-05-17 (Crawled : 12:00) - biospace.com/
GTHX | $4.075 -2.74% 84K
|
Health Technology
|
| O: -1.23%
H: 0.79%
C: -0.83%
lung cancer cancer
Gainers vs Losers
| 58% | 42% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Your saved searches
Save your searches and get alerts when important news are released.